An international team of researchers, led by Massachusetts General Hospital and Harvard Medical School, has conducted a ...

In mouse models, they found that the CSF Aβ42/40 ratio corresponded more closely to Aβ protofibrils in the brain than to plaques. In fact, statistical analyses determined that changes in the brain ...

The purpose of many compounds developed as potential treatments for Alzheimer's disease in recent years is to reduce the accumulation of amyloid-β peptide (Aβ) in the brain, a hallmark of the ...

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates). Aβ protofibrils ...

Oligomers of Aβ, tau, and ɑ-synuclein may be to blame, but their minuscule size makes them difficult to study through optical microscopy. Enter SynPull, a new synaptosome imaging method developed by ...